Evidence map›Paper›PMID 34196304›Full record

ArticleThe Journal of clinical investigation2021

Influenza vaccination in the elderly boosts antibodies against conserved viral proteins and egg-produced glycans.

Jiwon Jung, Sophia T Mundle, Irina V Ustyugova, Andrew P Horton, Daniel R Boutz, Svetlana Pougatcheva, Ponraj Prabakaran, Jonathan R McDaniel, Gregory R King, Daechan Park and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Defining and Studying B Cell Receptor and TCR Interactions.Journal of immunology (Baltimore, Md. : 1950) · 2023
    Article
  8. Article
  9. Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time.medRxiv : the preprint server for health sciences · 2022
    Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Jiwon JungDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas, USA.
Sophia T MundleSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Irina V UstyugovaSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Andrew P HortonDepartment of Chemical Engineering.
Daniel R BoutzDepartment of Molecular Biosciences.
Svetlana PougatchevaSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Ponraj PrabakaranSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Jonathan R McDanielDepartment of Chemical Engineering.
Gregory R KingInstitute for Cellular and Molecular Biology, and.
Daechan ParkInstitute for Cellular and Molecular Biology, and.
Maria D PersonBiological Mass Spectrometry Facility, The University of Texas at Austin, Austin, Texas, USA.
Congxi YeDepartment of Molecular Biosciences.
Bing TanDepartment of Chemical Engineering.
Yuri TannoDepartment of Chemical Engineering.
Jin Eyun KimDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas, USA.
Nicholas C CurtisThayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA.
Joshua DiNapoliSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Simon DelagraveSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Ted M RossCenter for Vaccines and Immunology, University of Georgia, Athens, Georgia, USA.
Gregory C IppolitoDepartment of Molecular Biosciences.
Harry KleanthousSanofi Pasteur Inc., Research North America, Cambridge, Massachusetts, USA.
Jiwon LeeThayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA.
George GeorgiouDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, Texas, USA.
AVEO Oncology (United States) · USThe University of Texas at Austin · USDartmouth College · USInstitut de Biologie Moléculaire et Cellulaire · FRUniversity of Georgia · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Virology CoreP01AI089618 · NIAID · BOSTON CHILDREN'S HOSPITAL · PI Jiwon Lee · 2011 to 2026
$40.0M
Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
Overall Priority Score P41GM103694 · NIGMS · EMORY UNIVERSITY · PI CUMMINGS, RICHARD D · 2013 to 2018
$6.9M
Protein-Glycan Interaction Resource at the National Center for Functional Glycomics (NCFG)R24GM137763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI RICHARD D CUMMINGS · 2020 to 2026
$5.8M
NIAID NIH HHS 75N93019C00052NIAID NIH HHS P01 AI089618NIGMS NIH HHS P20 GM113132NIGMS NIH HHS P41 GM103694NIGMS NIH HHS R24 GM137763
6 · The paper itself

Abstract

Seasonal influenza vaccination elicits a diminished adaptive immune response in the elderly, and the mechanisms of immunosenescence are not fully understood. Using Ig-Seq, we found a marked increase with age in the prevalence of cross-reactive (CR) serum antibodies that recognize both the H1N1 (vaccine-H1) and H3N2 (vaccine-H3) components of an egg-produced split influenza vaccine. CR antibodies accounted for 73% ± 18% of the serum vaccine responses in a cohort of elderly donors, 65% ± 15% in late middle-aged donors, and only 13% ± 5% in persons under 35 years of age. The antibody response to non-HA antigens was boosted by vaccination. Recombinant expression of 19 vaccine-H1+H3 CR serum monoclonal antibodies (s-mAbs) revealed that they predominantly bound to non-HA influenza proteins. A sizable fraction of vaccine-H1+H3 CR s-mAbs recognized with high affinity the sulfated glycans, in particular sulfated type 2 N-acetyllactosamine (Galβ1-4GalNAcβ), which is found on egg-produced proteins and thus unlikely to contribute to protection against influenza infection in humans. Antibodies against sulfated glycans in egg-produced vaccine had been identified in animals but were not previously characterized in humans. Collectively, our results provide a quantitative basis for how repeated exposure to split influenza vaccine correlates with unintended focusing of serum antibody responses to non-HA antigens that may result in suboptimal immunity against influenza.

Indexed as

AdultAgedAge FactorsAnimalsAntibodies, MonoclonalAntibodies, ViralCohort StudiesCross ReactionsEggsHumansImmunoglobulin GInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesMiddle AgedAntibodies, MonoclonalAntibodies, ViralImmunoglobulin GInfluenza VaccinesPolysaccharidesViral ProteinsAdaptive immunityInfectious diseaseInfluenzaVaccines

Identifiers

PMID34196304
PMCPMC8245176
OpenAlexW3176796948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.